Verona Pharma plc (NASDAQ:VRNA) CEO Sells $495,428.88 in Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 98,888 shares of Verona Pharma stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $5.01, for a total value of $495,428.88. Following the completion of the transaction, the chief executive officer now owns 15,078,624 shares in the company, valued at $75,543,906.24. The trade was a 0.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $16,000.00.
• On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $116,200.00.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The shares were sold at an average price of $4.39, for a total value of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Stock Up 3.1 %

NASDAQ:VRNA opened at $39.85 on Thursday. The stock’s fifty day moving average price is $35.26 and its two-hundred day moving average price is $25.89. Verona Pharma plc has a 52-week low of $11.39 and a 52-week high of $40.76. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -20.76 and a beta of 0.46.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The firm had revenue of $5.62 million during the quarter, compared to the consensus estimate of $2.31 million. During the same quarter in the prior year, the business posted ($0.18) earnings per share. On average, analysts anticipate that Verona Pharma plc will post -2.11 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VRNA. Eventide Asset Management LLC lifted its stake in shares of Verona Pharma by 359.6% in the 3rd quarter. Eventide Asset Management LLC now owns 2,425,846 shares of the company’s stock valued at $69,792,000 after purchasing an additional 1,898,065 shares during the period. Maverick Capital Ltd. lifted its stake in shares of Verona Pharma by 74.2% in the 2nd quarter. Maverick Capital Ltd. now owns 3,092,807 shares of the company’s stock valued at $44,722,000 after purchasing an additional 1,316,998 shares during the period. Loomis Sayles & Co. L P acquired a new position in shares of Verona Pharma in the 3rd quarter valued at $31,966,000. Candriam S.C.A. acquired a new position in shares of Verona Pharma in the 2nd quarter valued at $11,177,000. Finally, Jennison Associates LLC increased its position in shares of Verona Pharma by 54.3% in the 3rd quarter. Jennison Associates LLC now owns 1,740,886 shares of the company’s stock valued at $50,085,000 after buying an additional 612,854 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Ratings Changes

VRNA has been the topic of several recent analyst reports. HC Wainwright boosted their target price on Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Wells Fargo & Company boosted their target price on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Truist Financial boosted their target price on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Finally, Canaccord Genuity Group boosted their target price on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Verona Pharma has an average rating of “Buy” and an average price target of $43.83.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.